| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
GLP-1 receptor (GLP-1R). HAEGTFTSDVSSYLE is a peptide sequence found in GLP-1 analogs. It interacts with receptors that influence metabolic processes. As a component of GLP-1 analogs, it is involved in activating GLP-1R and mediating downstream metabolic effects, including insulin secretion and glucose regulation.
|
|---|---|
| ln Vitro |
HAEGTFTSDVSSYLE is a bioactive peptide that is part of the GLP-1 sequence found in GLP-1 analogs. It is known for its role in cellular signaling and interaction with receptors that influence metabolic processes. Its activity is related to GLP-1R activation and the subsequent regulation of glucose metabolism.
|
| ln Vivo |
In vivo, HAEGTFTSDVSSYLE, as part of GLP-1 analogs, would be expected to exert metabolic effects through GLP-1R activation. These effects include glucose-dependent insulin secretion, inhibition of glucagon release, and regulation of appetite and body weight. Its in vivo effects would be similar to those of GLP-1 receptor agonists.
|
| Enzyme Assay |
In vitro binding and functional assays are used to characterize HAEGTFTSDVSSYLE as a GLP-1R ligand. Radioligand binding assays or functional assays measuring cAMP accumulation are performed using GLP-1R-expressing cells to confirm its ability to activate GLP-1R and mediate downstream signaling.
|
| Cell Assay |
Cellular assays for HAEGTFTSDVSSYLE involve treating GLP-1R-expressing cells with the peptide and measuring receptor activation. Functional readouts include cAMP accumulation, a key downstream signal following GLP-1R activation. These assays confirm the peptide's ability to activate GLP-1R and mediate metabolic effects.
|
| Animal Protocol |
In vivo studies with HAEGTFTSDVSSYLE would be performed in animal models of diabetes and metabolic disorders. The peptide could be administered via injection, and its effects on glucose tolerance, insulin secretion, and metabolic parameters would be assessed. Its role as a GLP-1 analog would be evaluated in these models.
|
| ADME/Pharmacokinetics |
HAEGTFTSDVSSYLE is a peptide with molecular formula C71H103N17O28 and molecular weight of 1642.67-1642.71. As a peptide, its pharmacokinetic properties would be characteristic of this class, with a short half-life. The compound should be stored under recommended conditions. It is for research use only.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for HAEGTFTSDVSSYLE. As a GLP-1 analog peptide, its safety profile would be related to its pharmacological effects. Standard preclinical safety studies would be required to evaluate its safety for potential therapeutic applications.
|
| References | |
| Additional Infomation |
HAEGTFTSDVSSYLE (CAS#: 926018-57-7) is a bioactive peptide from patent CN 102920658 B. GLP-1 analogs contain this sequence. It is known for its role in cellular signaling and interaction with metabolic receptors. It has a molecular formula of C71H103N17O28 and a molecular weight of approximately 1642.7. It is a research tool for studying GLP-1 receptor function.
|
| Exact Mass |
1641.716
|
|---|---|
| CAS # |
926018-57-7
|
| PubChem CID |
156599142
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
26
|
| Hydrogen Bond Acceptor Count |
30
|
| Rotatable Bond Count |
51
|
| Heavy Atom Count |
116
|
| Complexity |
3380
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CNC=N3)N)O
|
| InChi Key |
IBFPRDPLWIXHBL-JSWOWQQASA-N
|
| InChi Code |
InChI=1S/C71H103N17O28/c1-32(2)21-44(61(105)78-43(71(115)116)18-20-53(98)99)79-62(106)45(23-38-13-15-40(94)16-14-38)80-65(109)48(28-89)83-67(111)50(30-91)84-68(112)55(33(3)4)87-64(108)47(25-54(100)101)81-66(110)49(29-90)85-70(114)57(36(7)93)88-63(107)46(22-37-11-9-8-10-12-37)82-69(113)56(35(6)92)86-51(95)27-74-60(104)42(17-19-52(96)97)77-58(102)34(5)76-59(103)41(72)24-39-26-73-31-75-39/h8-16,26,31-36,41-50,55-57,89-94H,17-25,27-30,72H2,1-7H3,(H,73,75)(H,74,104)(H,76,103)(H,77,102)(H,78,105)(H,79,106)(H,80,109)(H,81,110)(H,82,113)(H,83,111)(H,84,112)(H,85,114)(H,86,95)(H,87,108)(H,88,107)(H,96,97)(H,98,99)(H,100,101)(H,115,116)/t34-,35+,36+,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,55-,56-,57-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]pentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
